RxDoctor Payments Data

Lauren Ridderikhoff, DO

Family Medicine · Frankfort, KYNPI 1477915866

Payments from drug & device makers

$8,221in general payments, 2019–2025

Across 554 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Pfizer$566
  • AstraZeneca$499
  • Amgen$435
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,15999%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,221 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$44,249
Medicare patients
152
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide149$176,365
JardianceEmpagliflozin118$148,377
OzempicSemaglutide78$129,120
Repatha SureclickEvolocumab83$90,094
EliquisApixaban94$89,669
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$68,942
FarxigaDapagliflozin Propanediol58$61,215
VraylarCariprazine Hcl22$30,885
MyrbetriqMirabegron37$28,192
JanuviaSitagliptin Phosphate23$24,551
Tresiba Flextouch U-200Insulin Degludec29$23,137
TrulicityDulaglutide14$22,776
RybelsusSemaglutide14$20,351
LinzessLinaclotide18$19,934
XareltoRivaroxaban14$18,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,012$199,141163 claims
Novo NordiskOzempic, Rybelsus$1,406$149,47092 claims
Boehringer IngelheimJardiance$329$148,377118 claims
PfizerEliquis$566$89,66994 claims
GSKTrelegy Ellipta, Breo Ellipta$376$74,09580 claims
AstraZenecaFarxiga, Symbicort$499$66,60674 claims
AbbVieVraylar, Linzess, Synthroid$1,470$53,80495 claims
Astellas Pharma US IncMyrbetriq$97$28,19237 claims
MerckJanuvia$12$24,55123 claims
Johnson & JohnsonXarelto$159$18,64314 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$166$4,09311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →